Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
Kevin K. Brown
(1)
,
Yoshikazu Inoue
,
Kevin R. Flaherty
(2)
,
Fernando J. Martinez
(3)
,
Vincent Cottin
(4)
,
Francesco Bonella
(5)
,
Stefania Cerri
(6)
,
Sonye K. Danoff
(7)
,
Stéphane Jouneau
(8, 9)
,
Rainer-Georg Goeldner
(10)
,
Martin Schmidt
(10)
,
Susanne Stowasser
(10)
,
Rozsa Schlenker-Herceg
(10)
,
Athol U. Wells
(11, 12)
1
NJH -
National Jewish Health
2 University of Michigan [Ann Arbor]
3 Weill Cornell Medicine [Cornell University]
4 Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL]
5 Ruhrlandklinik University Hospital
6 Azienda Ospedaleria Universitaria di Modena = University Hospital of Modena
7 Johns Hopkins University School of Medicine [Baltimore]
8 Irset - Institut de recherche en santé, environnement et travail
9 EHESP - École des Hautes Études en Santé Publique [EHESP]
10 Boehringer Ingelheim Pharma GmbH & Co. KG
11 Imperial College London
12 Royal Brompton and Harefield NHS Foundation Trust
2 University of Michigan [Ann Arbor]
3 Weill Cornell Medicine [Cornell University]
4 Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL]
5 Ruhrlandklinik University Hospital
6 Azienda Ospedaleria Universitaria di Modena = University Hospital of Modena
7 Johns Hopkins University School of Medicine [Baltimore]
8 Irset - Institut de recherche en santé, environnement et travail
9 EHESP - École des Hautes Études en Santé Publique [EHESP]
10 Boehringer Ingelheim Pharma GmbH & Co. KG
11 Imperial College London
12 Royal Brompton and Harefield NHS Foundation Trust
Yoshikazu Inoue
- Fonction : Auteur
Vincent Cottin
- Fonction : Auteur
- PersonId : 784269
- ORCID : 0000-0002-5591-0955
- IdRef : 166774731
Francesco Bonella
- Fonction : Auteur
- PersonId : 784461
- ORCID : 0000-0001-7579-9767
Stéphane Jouneau
- Fonction : Auteur
- PersonId : 760799
- ORCID : 0000-0002-1949-3461
- IdRef : 124283659
Résumé
Background and objective Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality. Methods The relationships between baseline variables and time-varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model. Results Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1-year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1-unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1-unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia-like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1-unit increase) was associated with lower risk. Conclusion These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.
Domaines
Sciences du Vivant [q-bio]Format du dépôt | Fichier |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
|
Résumé |
en
Background and objective Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality. Methods The relationships between baseline variables and time-varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model. Results Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1-year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1-unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1-unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia-like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1-unit increase) was associated with lower risk. Conclusion These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.
|
Auteur(s) |
Kevin K. Brown
1
, Yoshikazu Inoue
, Kevin R. Flaherty
2
, Fernando J. Martinez
3
, Vincent Cottin
4
, Francesco Bonella
5
, Stefania Cerri
6
, Sonye K. Danoff
7
, Stéphane Jouneau
8, 9
, Rainer-Georg Goeldner
10
, Martin Schmidt
10
, Susanne Stowasser
10
, Rozsa Schlenker-Herceg
10
, Athol U. Wells
11, 12
1
NJH -
National Jewish Health
( 1091378 )
- 1400 Jackson Street, Denver CO 80206
- États-Unis
2
University of Michigan [Ann Arbor]
( 24332 )
- 500 Church Street Ann Arbor, MI 48109-1090
- États-Unis
3
Weill Cornell Medicine [Cornell University]
( 1055588 )
- 1300 York Avenue
New York, NY 10065
- États-Unis
4
Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL]
( 142181 )
- 69677 Bron Cedex
- France
5
Ruhrlandklinik University Hospital
( 1056744 )
- Tüschener Weg 40
45239 Essen
- Allemagne
6
Azienda Ospedaleria Universitaria di Modena = University Hospital of Modena
( 454913 )
- via del Pozzo 71 - 41124 Modena
- Italie
7
Johns Hopkins University School of Medicine [Baltimore]
( 148207 )
- 733 North Broadway, Suite G49
Baltimore, MD 21205-2196
- États-Unis
8
Irset -
Institut de recherche en santé, environnement et travail
( 182194 )
- 263 avenue Général Leclerc 35042 Rennes Cedex
- France
9
EHESP -
École des Hautes Études en Santé Publique [EHESP]
( 301986 )
- 15, avenue du Pr. Léon Bernard - 35043 Rennes Cedex
- France
10
Boehringer Ingelheim Pharma GmbH & Co. KG
( 467084 )
- Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany.
- Allemagne
11
Imperial College London
( 69530 )
- South Kensington Campus, London SW7 2AZ
- Royaume-Uni
12
Royal Brompton and Harefield NHS Foundation Trust
( 340534 )
- Royaume-Uni
|
Langue du document |
Anglais
|
Nom de la revue |
|
Volume |
27
|
Numéro |
4
|
Page/Identifiant |
294-300
|
Date de publication |
2022
|
Audience |
Internationale
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Licence |
Paternité
|
Domaine(s) |
|
Financement |
|
Mots-clés |
en
clinical trial, death, fibrosing interstitial lung disease, forced vital capacity, pulmonary fibrosis, pulmonary function test
|
DOI | 10.1111/resp.14231 |
Pubmed Id | 35224814 |
Origine :
Fichiers éditeurs autorisés sur une archive ouverte
Loading...